跳至主要内容
临床试验/NCT01525446
NCT01525446终止早期 1 期

Proton Stereotactic Body Radiation Therapy (SBRT) for Medically Inoperable, Peripheral Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Pilot Study

Massachusetts General Hospital2 个研究点 分布在 1 个国家目标入组 7 人开始时间: 2011年9月最近更新:
适应症

试验速览

阶段
早期 1 期
状态
终止
入组人数
7
试验地点
2
主要终点
Safety and tolerability

研究概览

简要总结

Stereotactic body radiation therapy (SBRT) is a special form of treatment which pinpoints high doses of radiation directly to cancer. Standard radiation (or photon radiation) is commonly used for SBRT to treat Non-Small Cell Lung Cancer (NSCLC). Proton beam radiation is a special type of radiation only available at a few institutions in the US and has not been previously used in SBRT to treat NSCLC. The use of protons for SBRT may improve the accuracy of the treatment and may help to minimize the dose delivered unnecessarily to healthy tissue.

In this study, the investigators are evaluating the safety and effectiveness of proton-based SBRT for early-stage NSCLC located in the periphery of the lung.

详细描述

Subjects will undergo an electronic navigational bronchoscopy (ENB) during which three markers will be placed around their tumor which will guide the delivery of proton beam radiation to their with more precision and accuracy.

Subjects will receive a CT scan to obtain images to plan radiation treatment. Proton radiation will be delivered daily (4 or 5 consecutive days) on an outpatient basis at Massachusetts General Hospital.

After the final dose of proton radiation subjects will be followed for 5 years. Subjects will be asked to return at 3 months, and then every 3 months until 2 years, and then every 6 months until 5 years. Subjects will receive a chest CT, tumor assessment by CT or PET, chest x-ray, pulmonary function tests and a physical exam.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically or cytologically confirmed non-small cell lung cancer (need not be newly diagnosed)
  • Stage clinical T1 N0 M0 or T2 N0 M0
  • NSCLC must be limited to a single lesion
  • NSCLC must be peripherally located (> 2 cm from proximal bronchial tree and > 1 cm from mediastinal pleura)
  • NSCLC must be considered medically inoperable
  • Life expectancy greater than 6 months

排除标准

  • Pregnant or breastfeeding
  • Prior radiation therapy to the lungs or mediastinum
  • Prior malignancy in the last 2 years unless treated definitively and disease free or carcinoma in situ or early stage skin cancers that have been definitively treated
  • Receiving other study agents or other types of cancer therapy
  • Uncontrolled intercurrent illness
  • Pacemaker or defibrillator-dependent

结局指标

主要结局

Safety and tolerability

时间窗: 2 years

Frequency of radiation pneumonitis in participants treated with proton radiation

Feasibility and safety

时间窗: 2 years

To establish the feasibility and safety of fiducials placement by electromagnetic navigational bronchoscopy (ENB)

次要结局

  • Toxicity(2 years)
  • Disease Free survival(2 years)
  • Efficacy(2 years)
  • Overall survival(2 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Henning Willers, M.D.

Attending Radiation Oncologist

Massachusetts General Hospital

研究点 (2)

Loading locations...

相似试验